EMG
ANTX icon

ETF Managers Group’s AN2 Therapeutics ANTX Stock Holding History

ETF Managers Group’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$66.5K Buy
+6,742
New +$75K ﹤0.01% 657
2022
Q4 		– Sell
-5,726
Closed -$100K – 524
2022
Q3 		$100K Sell
5,726
-404
-7% -$4.71K ﹤0.01% 651
2022
Q2 		$48K Buy
+6,130
New +$81.2K ﹤0.01% 712

Other funds holding ANTX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ETF Managers Group's ANTX Position: Q1 2023 in Review

ETF Managers Group opened a new position in AN2 Therapeutics (ANTX) in Q1 2023: 6,742 shares worth $66.5K. The stake represents ﹤0.01% of the portfolio and ranks #657 among its holdings. This is a return to the name: ETF Managers Group previously reported a position in ANTX as recently as Q3 2022.

ETF Managers Group first reported a position in ANTX in Q2 2022 and has held it in 3 quarters since. The position peaked at $100K in Q3 2022. 38 funds tracked by Wall St. Rank hold ANTX as of Q1 2023.

  • ETF Managers Group held 6,742 shares of AN2 Therapeutics worth $66.5K as of Q1 2023.
  • AN2 Therapeutics was a new ETF Managers Group position in Q1 2023.
  • AN2 Therapeutics made up ﹤0.01% of ETF Managers Group's portfolio in Q1 2023, its #657 holding.
  • ETF Managers Group first reported a position in AN2 Therapeutics in Q2 2022 and has held it in 3 quarters since.
  • ETF Managers Group's AN2 Therapeutics position peaked at $100K in Q3 2022.
  • 38 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2023.

Based on ETF Managers Group's 13F filing for Q1 2023, filed 18 Apr 2023.